 TRACON Pharmaceuticals NASDAQ:TCON Inc said it has ended its fiscal year 2021 with cash and equivalents of 24.1 million as of December 31, 2021, as the company outlined some key milestones for the coming year. TRACON noted that it anticipates an interim ENVASARC safety and efficacy data review by the Independent Data Monitoring Committee IDMC in the second half of 2022. 